GNOG.L vs. SBIO.L
Compare and contrast key facts about Global X Genomics & Biotechnology UCITS ETF (GNOG.L) and Invesco Nasdaq Biotech UCITS ETF (SBIO.L).
GNOG.L and SBIO.L are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. GNOG.L is a passively managed fund by Global X that tracks the performance of the MSCI World/Health Care NR USD. It was launched on Nov 2, 2021. SBIO.L is a passively managed fund by Invesco that tracks the performance of the NASDAQ Biotechnology TR USD. It was launched on Nov 6, 2014. Both GNOG.L and SBIO.L are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Performance
GNOG.L vs. SBIO.L - Performance Comparison
Loading graphics...
GNOG.L vs. SBIO.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
GNOG.L Global X Genomics & Biotechnology UCITS ETF | -1.16% | 12.03% | -16.98% | -11.35% | -29.74% | -10.30% |
SBIO.L Invesco Nasdaq Biotech UCITS ETF | 5.17% | 23.42% | -0.28% | 0.83% | -1.37% | -6.21% |
Different Trading Currencies
GNOG.L is traded in GBP, while SBIO.L is traded in USD. To make them comparable, the SBIO.L values have been converted to GBP using the latest available exchange rates.
Returns By Period
In the year-to-date period, GNOG.L achieves a -1.16% return, which is significantly lower than SBIO.L's 5.17% return.
GNOG.L
- 1D
- 3.29%
- 1M
- -4.36%
- YTD
- -1.16%
- 6M
- 14.72%
- 1Y
- 37.00%
- 3Y*
- -4.91%
- 5Y*
- —
- 10Y*
- —
SBIO.L
- 1D
- 2.20%
- 1M
- 0.06%
- YTD
- 5.17%
- 6M
- 19.42%
- 1Y
- 36.22%
- 3Y*
- 10.55%
- 5Y*
- 5.56%
- 10Y*
- 8.81%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
GNOG.L vs. SBIO.L - Expense Ratio Comparison
GNOG.L has a 0.50% expense ratio, which is higher than SBIO.L's 0.40% expense ratio.
Return for Risk
GNOG.L vs. SBIO.L — Risk / Return Rank
GNOG.L
SBIO.L
GNOG.L vs. SBIO.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology UCITS ETF (GNOG.L) and Invesco Nasdaq Biotech UCITS ETF (SBIO.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| GNOG.L | SBIO.L | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.23 | 1.63 | -0.40 |
Sortino ratioReturn per unit of downside risk | 1.79 | 2.20 | -0.41 |
Omega ratioGain probability vs. loss probability | 1.22 | 1.29 | -0.07 |
Calmar ratioReturn relative to maximum drawdown | 2.22 | 3.53 | -1.32 |
Martin ratioReturn relative to average drawdown | 6.61 | 12.80 | -6.19 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| GNOG.L | SBIO.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.23 | 1.63 | -0.40 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.27 | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.39 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.45 | 0.33 | -0.78 |
Correlation
The correlation between GNOG.L and SBIO.L is 0.81, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
GNOG.L vs. SBIO.L - Dividend Comparison
Neither GNOG.L nor SBIO.L has paid dividends to shareholders.
Drawdowns
GNOG.L vs. SBIO.L - Drawdown Comparison
The maximum GNOG.L drawdown since its inception was -67.50%, which is greater than SBIO.L's maximum drawdown of -34.90%. Use the drawdown chart below to compare losses from any high point for GNOG.L and SBIO.L.
Loading graphics...
Drawdown Indicators
| GNOG.L | SBIO.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.50% | -39.44% | -28.06% |
Max Drawdown (1Y)Largest decline over 1 year | -17.16% | -14.07% | -3.09% |
Max Drawdown (5Y)Largest decline over 5 years | — | -38.33% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -38.33% | — |
Current DrawdownCurrent decline from peak | -48.74% | -2.55% | -46.19% |
Average DrawdownAverage peak-to-trough decline | -44.07% | -17.03% | -27.04% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.75% | 2.85% | +2.90% |
Volatility
GNOG.L vs. SBIO.L - Volatility Comparison
Global X Genomics & Biotechnology UCITS ETF (GNOG.L) has a higher volatility of 9.63% compared to Invesco Nasdaq Biotech UCITS ETF (SBIO.L) at 7.40%. This indicates that GNOG.L's price experiences larger fluctuations and is considered to be riskier than SBIO.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| GNOG.L | SBIO.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.63% | 7.40% | +2.23% |
Volatility (6M)Calculated over the trailing 6-month period | 21.09% | 14.17% | +6.92% |
Volatility (1Y)Calculated over the trailing 1-year period | 29.88% | 22.10% | +7.78% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 31.32% | 20.89% | +10.43% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 31.32% | 22.60% | +8.72% |